Tube Investments of India is a diversified engineering group with four reporting segments: engineering (tubes and metal formed products), mobility (electric vehicles), medical devices, and a CDMO, alongside majority stakes in CG Power and Shanthi Gears. The core money maker is the engineering and metal formed products business, which generated FY26 revenue of Rs.7,215 crore (engineering Rs.5,612 crore plus metal formed Rs.1,603 crore) with a combined PBIT of Rs.851 crore, implying a mid-teens operating margin. The group's return on invested capital is exceptional at 44% for FY26, and free cash flow matched PAT at Rs.826 crore, indicating that the legacy businesses are highly cash-generative. In the electric truck segment, the company holds a 28% market share despite 11 players, and a 27% share in small commercial vehicles, showing niche dominance in an emerging market.
The persistence of these economics rests on a mix of qualification cycles, switching costs, and converter economics. Automotive components require long validation cycles with OEMs, and the company's relationships with customers like Hyundai (which is ramping a new western plant) create sticky revenue. The steel price pass-through mechanism, though lagged by two to three quarters, ensures margin recovery over time, as management confirmed in August 2026 that Q4 and Q1 steel increases will be fully recovered. The EV business, while loss-making, has a first-mover advantage with the Montra Rhino being the first electric truck certified under PM E-drive, and its solution-selling approach (including financing and charging support) differentiates it from commodity truck makers. However, the engineering business is not immune to cyclicality; the metal formed products segment saw PBIT decline from Rs.37 crore to Rs.28 crore in Q1 FY27, and the railway business remains a drag. Still, the high ROIC and free cash flow conversion suggest that the core is not a commodity scale game but a specialized converter with pricing power.
The inflection over the next 18-24 months is driven by three simultaneous capacity and product cycles. First, the CDMO facility at Naidupet has commissioned 200 KL of reactor capacity, with validation batches ongoing and a cleanroom expected within 30-40 days as of August 2026; customer inspections are slated for the next financial year, and 15 customers are already working on FTA/FFS and semi-commercial projects. Second, TI Medical is targeting 20% revenue growth with profitability, and the Medicura IV cannula acquisition will start generating revenue from August/September 2026. Third, the EV business is scaling: volumes increased quarter-on-quarter, with 86 big trucks, 1,924 three-wheelers, and 347 small commercial vehicles sold in Q1 FY27, and management expects one EV business to break even this fiscal year and two more next fiscal year. By mid-2028, the company should have a fully ramped CRSS plant at Nasik (100% utilization by end FY27), tube facilities in the West at full utilization, and a stabilized Hyundai plant, while the railway business could convert its prototype into orders if government approvals for Vande Bharat coaches materialize within the guided 2-3 quarters.
Management's walk-talk has been mixed but transparent. In May 2026, they promised EV breakeven during FY26, which they later admitted was unlikely, pushing the target to the next 12-18 months. Capex timelines also slipped: the western plant for metal formed products was delayed by six months, and the railway order that was expected in Q4 FY26 moved to FY27. However, the core engineering division delivered double-digit volume growth, the Rs.1,000 crore railway contract was secured as planned, and standalone double-digit revenue guidance was maintained. In August 2026, management reiterated commitments: steel price recovery in coming quarters, medical growth of 20% with profitability, CDMO cleanroom in 30-40 days, and a second tranche of Rs.250 crore infusion into subsidiaries in Q3. Capital allocation remains disciplined with FY27 capex of Rs.600-700 crore (excluding CG Power) and a strong balance sheet that generated Rs.174 crore of free cash flow in Q1 alone.
The quantified earnings path over the next two years hinges on three variables: standalone EBIT margin recovery to double digits as steel pass-through completes, EV losses narrowing to breakeven, and medical/CDMO scaling to contribute incremental revenue. If management executes, consolidated revenue could grow from Rs.22,847 crore in FY26 to over Rs.28,000 crore by FY28, with a higher mix of higher-margin medical and EV revenue. The kill shot is a further slip in EV breakeven or a delay in CDMO customer approvals, which would extend the cash burn and undermine the transformation narrative. The key watchpoint is the EV business's ability to achieve the promised breakeven within the next 12-18 months, given cell price inflation and financing challenges for large deployments. The tension between missed EV deadlines and strong core performance resolves as an execution miss in new ventures, not a structural decline in the legacy business, which continues to generate high returns and cash flow.
companyname: Tube Investments of India Limited ticker: TIINDIA sector: Diversified Engineering, Manufacturing, Mobility & New Ventures Tube Investments of India (TII) is a Chennai-based diversified engineering company controlled by the Murugappa Group. Its standalone business makes precision steel tubes, cold rolled steel strips, automotive chains, fine blanked components, roll-formed car door frames, bicycles, and industrial chains. Through subsidiaries it also owns CG Power (electrical equipm...
Read the full report →capex, margin expansion, regulatory approval, acquisition inorganic
TI Medical business guided to grow between 15-20% year-on-year driven by new product development and plant approvals
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Tube Investments of India Limited and 4,900+ companies.
5-day free pass. No card required.